CDA | Evidence Driven
CDA | Evidence Driven

dapagliflozin

Details

Files
Generic Name:
dapagliflozin
Project Status:
Complete
Therapeutic Area:
Chronic kidney disease
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0749-000 - SR0749-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
N/A
Indications:
It is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular and renal death in adults with chronic kidney disease (CKD).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Key Milestones2
Call for patient/clinician input open30-Jun-22
Call for patient/clinician input closed22-Aug-22
Clarification:

- Patient input submission received from CARP (Canadian Association of Retired Persons), and The Kidney Foundation of Canada

Call for industry input open30-Jun-22
Call for industry input closed22-Aug-22
Clarification:

- Patient input submission received from Canadian Association of Retired Persons and The Kidney Foundation of Canada

Expert committee meeting (initial)29-Jun-23
Draft recommendation posted for stakeholder feedback20-Jul-23
End of feedback period03-Aug-23
Final recommendation posted23-Aug-23
CADTH review report(s) posted23-Aug-23

Files

Recommendation and Reasons View PDF
Responses to Questions From the Drug Programs View PDF
Clinical and Pharmacoeconomic Combined Report View PDF
Stakeholder Input View PDF
Stakeholder Feedback on Draft Recommendation View PDF
Last Updated : September 8, 2023